009 Prikazi.p65
ثبت نشده
چکیده
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
منابع مشابه
009 Prikazi.p65
2 + )*$ *" $ M 7 " 3 $ 4 5 $ + ,$ ) $ $ ( " , * ! $ !$( $/ H + 6 $ " +$ " $ +$ $( )*$ *"$ ( 6 " + $/ + $ + !$ + $ + ! , $ " ) " " ($ 0$ " )*$ " * + , $ *"$ " $ + 0 / +$ " $*$ "$ $ $ $ *$ " ! " 6 *" , , $ $ $ , !$( " / +$ " , *$ .+ # $ $+ $ *"$ " $( ($( " , + *" ($ * $ + , *$ .+ ( + (+ $ $ $ + $ +/ + )*$ 6 " .$ $* $+ $ , + $0 ( "$ " , *$ " . " $ 1 $* $ + + 6 "$ , 0$ " 1+ "$ $/ 2 + )*$ *" H $ $ $...
متن کامل11 Prikazi.p65
) # ! $ ( 5 H : % 0 ; # # A6 # AA # " # " " ' K $ % $ $ ! 1 ! $ # ' ! " ( ' # $ + # + B ! E ! ! ( , A6P $ # * + # H $ ! % A0 $ # " ! * $ " ! 7 # # * 9 + ! * K $ ! % ! ) # ! $ 7 ' 5 4 : 0 %66P ; ! # ! ! K $ H 4 + ! % ! ! + * H * 7 ! ! % # # " # ' ! K $ 1 ! ( ! * ! ( ! H & H ( $ * # ' $ ! # ! " ! # % # $ # 5 $ , I # ! # ! 2 $ ! ( * ! ' ( 2 $ # ' " ! ! ( $ ' ' ! " $ " ( # ! $ $ % ! * $ $ * * " ! #...
متن کامل[Effects of cernitin pollen extract (CN-009) on the isolated bladder smooth muscles and the intravesical pressure].
Cernitin pollen extract (CN-009), extract from several pollen species, has been used for urinary dysfunction. As its mode of action has not been clarified, we investigated the action of CN-009 on the isolated bladder smooth muscles of rats, guinea pigs and cats and the intravesical pressure in female rats. CN-009 contracted isolated detrusor muscles of rats, guinea pigs and cats in a concentrat...
متن کاملCancer Therapy: Clinical Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Purpose: MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). M...
متن کاملPhase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
PURPOSE MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2006